Evidence map›Paper›PMID 38779691›Full record

ArticleUrology case reports2024

A case of severe side effects to androgen receptor inhibitor and consequently switch to radioligand therapy in early castration resistant prostate cancer.

Andreas Tulipan, Clemens Kratochwil, Jacob Lilleby, Wolfgang Lilleby

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.European journal of nuclear medicine and molecular imaging · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andreas TulipanOslo University Hospital, Dept of Nuclear Medicine, Oslo, Norway.
Clemens KratochwilHeidelberg University Hospital, Dept. of Nuclear Medicine, Heidelberg, Germany.
Jacob LillebyRiga Stradins University, Faculty of Medicine, Riga, Latvia.
Wolfgang LillebyOslo University Hospital, Cancer Clinic-Radiumhospitalet, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of potent novel androgen receptor inhibitors (ARi) such as apalutamide have improved the life expectancy in men with castration-resistant prostate cancer (CRPCa). However, some serious toxicity can occur limiting the choice of treatment in CRPCa. In our case, the patient experienced severe toxicity after initiation of apalutamide. Diagnostic PSMA-PET/CT confirmed the recurrence and tailored the treatment with

Indexed as

Androgen receptor inhibitorProstate cancerRadioligand therapy

Identifiers

PMID38779691
PMCPMC11109734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.